Page last updated: 2024-11-07

aldosterone and Growth Disorders

aldosterone has been researched along with Growth Disorders in 11 studies

Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.

Research Excerpts

ExcerptRelevanceReference
"In salt-losing congenital adrenal hyperplasia (CAH), treatment with a mineralocorticoid in doses that normalized plasma renin activity (PRA) induced a marked increase in linear growth."1.27The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. ( Gunzcler, P; Kuhnle, U; Levine, LS; New, MI; Pareira, JA; Rösler, A, 1983)
"Three children with a Bartter's syndrome have been investigated: all of them had growth retardation, hypokalemia (less than 3 mmol/l), raised plasma renin activity and urinary prostaglandins (PGE2 and PGF2 alpha) and a decreased sensibility for angiotensin."1.26[Bartter's syndrome: seven cases in siblings. Hypothesis of mild forms (author's transl)]. ( Bagros, P; Benatre, A; Dray, F; Drucker, J; Grenier, B; Lebranchu, Y; Nivet, H; Rolland, JC, 1980)
"Six children with Bartter's syndrome aged 6 years 4 months to 13 years 11 months were treated with indomethacin (1."1.26[Bartter's syndrome: the long term effects of indomethacin on growth (author's transl)]. ( David, M; Floret, D; Hage, GN; Roux, A; Teyssier, G, 1979)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19907 (63.64)18.7374
1990's3 (27.27)18.2507
2000's0 (0.00)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mital, S1
Chung, WK1
Colan, SD1
Sleeper, LA1
Manlhiot, C1
Arrington, CB1
Cnota, JF1
Graham, EM1
Mitchell, ME1
Goldmuntz, E1
Li, JS1
Levine, JC1
Lee, TM1
Margossian, R1
Hsu, DT1
Kuhnle, U1
Rösler, A1
Pareira, JA1
Gunzcler, P1
Levine, LS1
New, MI1
Nivet, H1
Rolland, JC1
Lebranchu, Y1
Dray, F1
Benatre, A1
Drucker, J1
Grenier, B1
Bagros, P1
Barton, JS1
Hindmarsh, PC1
Preece, MA1
Brook, CG1
DiMartino-Nardi, J1
Wesoly, S1
Schwartz, L1
Saenger, P1
Floret, D1
David, M1
Roux, A1
Hage, GN1
Teyssier, G1
Laue, L1
Pizzo, PA1
Butler, K1
Cutler, GB1
Bodin, G1
Rival, JM1
Gillot, F1
Kershnar, AK1
Roe, TF1
Kogut, MD1
Ramanathan, K1
Gantt, C1
Grossman, A1
Canale, VC1
Steinherz, P1
New, M1
Erlandson, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)[NCT00113087]Phase 3230 participants (Actual)Interventional2003-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

B-Type Natriuretic Peptide

B-Type Natriuretic Peptide (BNP) level. (NCT00113087)
Timeframe: Measured just prior to the Glenn surgery

Interventionpg/ml (Median)
Enalapril79
Placebo84

B-type Natriuretic Peptide Level

B-type natriuretic peptide (BNP) level. (NCT00113087)
Timeframe: at the time of the 14 month visit

Interventionpg/ml (Median)
Enalapril25
Placebo39

Ejection Fraction (%)

Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume. (NCT00113087)
Timeframe: at 14 months of age

Interventionpercent (of end diastolic volume) (Mean)
Enalapril59.3
Placebo57.9

Ejection Fraction (%)

Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume. (NCT00113087)
Timeframe: just before the Glenn surgery

Interventionpercent (of end diastolic volume) (Mean)
Enalapril57.9
Placebo56.6

End Diastolic Volume Z-score

Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Interventionstandard deviation (Mean)
Enalapril2.3
Placebo2.1

End-diastolic Volume

Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

Interventionml (Mean)
Enalapril29.2
Placebo30.7

End-diastolic Volume

Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Interventionml (Mean)
Enalapril24.1
Placebo23.2

End-diastolic Volume Z-score

Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril1.1
Placebo1.3

Head Circumference-for-age Z-score

Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

Interventionstandard deviation (Least Squares Mean)
Enalapril-0.55
Placebo0.09

Height-for-age Z-score

Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

Interventionstandard deviation (Least Squares Mean)
Enalapril-1.00
Placebo-0.86

MacArthur-Bates Inventory -Phrases Understood

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril-0.48
Placebo-0.92

MacArthur-Bates Inventory -Total Gestures

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril-0.86
Placebo-1.31

MacArthur-Bates Inventory -Words Produced

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Median)
Enalapril-0.60
Placebo-0.63

MacArthur-Bates Inventory -Words Understood

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril-0.46
Placebo-0.82

Neurodevelopmental Status (FSII)

Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders. (NCT00113087)
Timeframe: at 14 months of age

Interventionunits on a scale (Median)
Enalapril96.4
Placebo96.4

Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score

"Neurodevelopmental status (PDI):~the Bayley Scales of Infant Development: Psychomotor Development index z-score ." (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril-1.29
Placebo-1.32

Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score

Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score . (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril-0.26
Placebo-0.33

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of participants with moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: at age 14 months

Interventionparticipants (Number)
Enalapril11
Placebo22

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of participants with Moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: just before the pre-Glenn surgery

Interventionparticipants (Number)
Enalapril20
Placebo32

Number of Participants With Ross Heart Failure Class I

Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Just prior to the pre-Glenn surgery

InterventionParticipants (Number)
Enalapril53
Placebo56

Number of Participants With Ross Heart Failure Class I

Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Measured at 14 months of age

Interventionparticipants (Number)
Enalapril72
Placebo77

Ventricular Filling Pressure

Ventricular filling pressure measured by catherization (NCT00113087)
Timeframe: just before the Glenn surgery

InterventionmmHg (Mean)
Enalapril10.9
Placebo11.1

Ventricular Mass

Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Interventiong (Mean)
Enalapril25.5
Placebo28.1

Ventricular Mass

Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40 (NCT00113087)
Timeframe: At 14 months of age

Interventiong (Mean)
Enalapril31.4
Placebo34.4

Ventricular Mass to Volume Ratio

Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured at 14 months of age

Interventiong/ml (Mean)
Enalapril1.14
Placebo1.20

Ventricular Mass to Volume Ratio

Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured just before the Glenn surgery

Interventiong/ml (Mean)
Enalapril1.15
Placebo1.31

Ventricular Mass Z-score

Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age

Interventionstandard deviation (Mean)
Enalapril2.5
Placebo3.1

Ventricular Mass Z-score

Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery

Interventionstandard deviation (Mean)
Enalapril4.0
Placebo4.9

Weight-for-age Z-score at 14 Months of Age

Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age

Interventionstandard deviation (Least Squares Mean)
Enalapril-0.62
Placebo-0.42

Trials

3 trials available for aldosterone and Growth Disorders

ArticleYear
Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle.
    Circulation, 2011, May-31, Volume: 123, Issue:21

    Topics: Aldosterone; Angiotensins; Cohort Studies; Double-Blind Method; Female; Genotype; Growth Disorders;

2011
Blood pressure and the renin-angiotensin-aldosterone system in children receiving recombinant human growth hormone.
    Clinical endocrinology, 1993, Volume: 38, Issue:3

    Topics: Aldosterone; Blood Pressure; Body Water; Body Weight; Child; Female; Growth Disorders; Growth Hormon

1993
Lack of clinical evidence of sodium retention in children with idiopathic short stature treated with recombinant growth hormone.
    Metabolism: clinical and experimental, 1993, Volume: 42, Issue:6

    Topics: Aldosterone; Atrial Natriuretic Factor; Body Height; Child; Female; Growth Disorders; Growth Hormone

1993

Other Studies

8 other studies available for aldosterone and Growth Disorders

ArticleYear
The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency.
    Acta endocrinologica, 1983, Volume: 102, Issue:4

    Topics: 17-alpha-Hydroxyprogesterone; Addison Disease; Adolescent; Adrenal Hyperplasia, Congenital; Aldoster

1983
[Bartter's syndrome: seven cases in siblings. Hypothesis of mild forms (author's transl)].
    La Nouvelle presse medicale, 1980, Apr-19, Volume: 9, Issue:18

    Topics: Adolescent; Aldosterone; Angiotensin II; Bartter Syndrome; Child; Female; Growth Disorders; Humans;

1980
[Bartter's syndrome: the long term effects of indomethacin on growth (author's transl)].
    La Nouvelle presse medicale, 1979, Jan-06, Volume: 8, Issue:1

    Topics: Adolescent; Aldosterone; Bartter Syndrome; Body Height; Body Weight; Bone Development; Child; Cycloo

1979
Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome.
    The Journal of pediatrics, 1990, Volume: 117, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adrenocorticotropic Hormone; Aldosterone; Child; Child, Preschoo

1990
[Chronic idiopathic hypokalemia with hyperkaliuria in a very young infant. (Bioclinical and histological study)].
    Annales de pediatrie, 1969, Nov-02, Volume: 16, Issue:11

    Topics: Aldosterone; Alkalosis; Angiotensin II; Calcium; Chlorides; Diet, Sodium-Restricted; Growth Disorder

1969
Adrenocorticotropic hormone unresponsiveness: report of a girl with excessive growth and review of 16 reported cases.
    The Journal of pediatrics, 1972, Volume: 80, Issue:4

    Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aldosterone; Arginine; Child; Corticoster

1972
Six year follow-up of a child with Bartter syndrome.
    American journal of diseases of children (1960), 1973, Volume: 126, Issue:2

    Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema

1973
Endocrine function in thalassemia major.
    Annals of the New York Academy of Sciences, 1974, Volume: 232, Issue:0

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adult; Age Determination by Skeleton; Aldost

1974